Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

SUPPLEMENTARY MATERIALS Patient cohort demographics, B-cell or peripheral blood mononuclear cell (PBMC) isolation and cell culture
The patient cohort (n=26) included in the study were considered very high risk for disease progression based on FISH panel assessment (i.e. eight were 17p-and seven were 11q-by FISH) and IgVH mutation status (17 unmutated). Twenty two (n=22) patients were treated with ibrutinib for progressive disease, two (P6 and P7) had relapsed while on ibrutinib. Two patients (P25 and P26; one relapsed after chemo-immunotherapy and the other relapsed while on rituximab) were scheduled for ibrutinib treatment and thus considered as baseline patients (pre ibrutinib therapy) for the study. Out of 26 patients, 11 were studied sequentially from the initial start of ibrutinib therapy and then over a two year follow-up period. The median number of prior therapies was 2.0, range (0-12). Patients provided initial blood samples at a median of 2.9 months (range: 3 -21.5 months) after ibrutinib therapy initiation for the in vitro studies reported here. All patients provided written informed consent according to the Declaration of Helsinki to the Mayo Clinic Institutional Review Board, which approved these studies.
Primary CLL B-cells were isolated and purified from blood of the CLL patients using the RosetteSep B-cell enrichment kit (Stem Cell Technologies). The purification range of CD5 + /CD19 + CLL B-cells was >95-99%. Cells were cultured in serum-free AIM-V (GIBCO) medium as needed. PBMCs were isolated from blood by Ficoll.
Reagents
A high-affinity orally bioavailable Axl inhibitor TP-0903 (tartrate salt) and TP-0903 (free base) was provided by Tolero Pharmaceuticals Inc., Bcl-2 antibody was purchased from BD Pharmingen and antibodies to Actin and Axl were purchased from Santa Cruz Biotechnologies. Tyro3 and MER antibodies were obtained from Abcam and Lifespan Biosciences, respectively. Phosphotyrosine mouse monoclonal antibody (4G10) was obtained from Millipore. All other antibodies were obtained from Cell Signaling Technology.
Treatment of CLL B-cells with TP-0903 and induction of apoptosis CLL B-cells (2 x 10
6 cells/ml) from CLL patients (previously untreated or ibrutinib exposed) were treated with increasing doses of TP-0903 (either freebase or tartrate salt) (0.01-0.50μM) for 24 hours in serum-free AIM-V media. PBMCs (2 x 10 6 cells/ml) from healthy normals were also treated with increasing doses of TP-0903 (tartrate salt) (0.01-0.50μM) for 24 hours in 10% RPMI medium. TP-0903 treated PBMCs or CLL B-cells were harvested, and induction of apoptosis determined by flow cytometry (FACScan, Becton Dickinson) after staining the cells with Annexin V/propidium iodide (PI) as described [16] .
Immunoprecipitation and western blot analysis
For immunoprecipitation (IP) experiments, 0.2-0.3 mg of CLL B-cell lysates was used to IP using appropriate antibodies as described elsewhere [16] . The precipitated immune complex was electrophoresed on SDSpolyacrylamide gels and transferred onto nitrocellulose membranes, and proteins of interest were detected using specific antibodies. CLL B-cell lysates were analyzed for the expressions of Axl, XIAP, Bcl-2, and Mcl-1by Western blot. CLL B-cell lysates were also analyzed for the phosphorylation status of Axl, Btk, AKT and ERK-1/2 using specific antibodies by Western blot.
Reverse transcription polymerase chain reaction (PCR)
Total cellular RNA was extracted using Purelink Mini Kit (Invitrogen) and 1 μg was reverse transcribed using the SuperScript® III First Strand Synthesis Kit (Invitrogen) and PCR was performed using the SYBR Green PCR core Master Mix (Applied Biosystems, Foster City, CA, USA) on a 7500 Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. GAPDH was used for cDNA normalization. Btk, Axl and GAPDH primers were purchased from SABiosciences (Frederick, MD, USA).
The study was done using fasting, male Sprague Dawley rats. Both the free base form of TP-0903 and the tartrate salt were formulated in 20% solutol. The free base of TP-0903 was formulated at 5.0 mg/ml (PO) and dosed by oral gavage (18.2 mg/kg). The tartrate salt of TP-0903 was formulated at 6.5 mg/ml to account for the added weight of the salt and dosed by oral gavage (14.5 mg/kg). Plasma samples were taken at 0. 25, 0.5, 1, 2, 4, 8, 12 and 24 h and analyzed for TP-0903 concentration by LC-MS/ MS with reference to a previously determined standard curve. Pharmacokinetic parameters were calculated using a non-compartmental approach with Phoenix WinNonlin 6.3 (Pharsight, Mountain View, CA, USA).
Statistical analysis
CLL prognostic factors (i.e. ZAP70, FISH, IgVH mutation status, Rai stage, CD38, and CD49d) were evaluated for association with TP-0903 apoptosis induction data of the respective CLL B-cells. Associations between prognostic factors and TP-0903 drug sensitivity were computed using the Kruskal-Wallis test for continuous variables and Chi-square test for categorical variables. SAS 9.4 (SAS Institute, Cary, NC, USA) was used for data analysis. The p-values were generated using a paired t-test. 
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